Articles in category "Latest News"

June 28, 2014

Women In Bio: Interview with BioSurplus’ Dawn Hocevar

Last November, BioSurplus’ VP of business development, Dawn Hocevar was interviewed by Ed Miseta, chief editor of Outsourced Pharma.  The piece was part of a series of interviews with women executives in the biotech and pharma industries sponsored by the organization Women In Bio (WIB). Hocevar, in addition to her role at BioSurplus is also currently serving as WIB’s national chair of programs and development, where she works with local chapters to execute programs that promote careers, leadership and entrepreneurship for women in the life sciences. Over her 20-plus year career, Dawn Hocevar has developed a deep knowledge of laboratory […]

Read the full post

June 19, 2014

Heading To BIO 2014? Favorite Places To Visit In San Diego

Are you heading to San Diego for BIO 2014 next week?  If so, do you know how you’re going to spend your free time while you’re here? With so much to do during the conference itself, that free time just might be limited.  But if you do have a chance to get away, San Diego offers some great places for you to spend it.  And it’s not all about the beach and surfing…. Jennifer Landress, Senior VP and COO of BIOCOM, recently posted an excellent list of local attractions on the BIOtechNOW blog.  BioSurplus is a BIOCOM member and a […]

Read the full post

June 16, 2014

Roche Announces Acquisition Of Sequencing Technology Firm Genia

Basel, Switzerland-based pharma giant Roche announced on June 2 that it has acquired Genia Technologies of Mountain View, CA, a next-gen sequencing technology company whose nanopore-based platform allows for rapid DNA sequencing using integrated circuits. BioSurplus’ Antonio Johnson previously wrote about Genia’s technology on the BioSurplus blog.  Take a moment to read the article here. The $125 million acquisition, with a potential further payout of $225 million to investors upon completion of certain milestones, is part of Roche’s plan to develop its own sequencing platform on which it can base its diagnostic products.  The company bought 454 Life Sciences, an […]

Read the full post

June 13, 2014

Venter Institute Awarded Grant For Infectious Disease Genome Center

The J. Craig Venter Institute (JCVI) announced on Thursday, June 5, that it has been awarded a grant of approximately $25 million from the National Institute of Allergy and Infectious Diseases (NAID). The funding, to be provided over a five-year period, will enable the establishment and operation of a Genome Center for Infectious Diseases (GCID).  The center’s primary goal will be to further the scientific understanding of infectious diseases by focusing on the pathogens that cause them.  Research results will be made available to the greater scientific community. Infectious diseases continue to be a worldwide scourge and are one of […]

Read the full post

June 9, 2014

UCSF Researchers Use Next-Gen Sequencing For Rapid Diagnosis

For the first time, researchers have used next-gen DNA sequencing to make an actionable diagnosis on a patient.  A report of the case was published in an article in the New England Journal of Medicine this Wednesday, June 4. 14-year old Joshua Osborne, of Madison Wisconsin, had been placed in a medically induced coma last July due to severe swelling in his brain.  When testing for multiple diseases turned up nothing, his doctor, James Gern, of the University of Wisconsin School of Medicine, reached out to two of his fellow research collaborators:  Dr. Joseph DeRisi, and his colleague, pathologist Dr. […]

Read the full post

June 6, 2014

FDA Lifts Hold On Trial Of Halozyme Pancreatic Cancer Drug

San Diego-based Halozyme Therapeutics announced on Wednesday that the FDA has lifted a hold on a clinical trial of its pancreatic cancer drug, PEGPH20. The hold on patient enrollment and dosing was put in place this April when the company, based on recommendations from an independent data monitoring committee, decided to evaluate a possible increase in the rate of thromboembolism, or blood clots, in patients treated with PEGPH20. After reviewing data, the committee recommended last month that the trial (Study 202) be resumed under revised protocols.  Patients considered to be at a high risk of thromboembolic events will be excluded […]

Read the full post

May 30, 2014

2014 Kavli Science Prize Winners Announced

The winners of this year’s Kavli Prizes were officially announced yesterday, Thursday, May 29.  Nine scientists from around the world will share in each of three $1 million prizes, awarded in the fields of astrophysics, nanoscience and neuroscience. The biennial Kavli Prizes were established in 2005 as a partnership between the Kavli Foundation, the Norwegian Academy of Science and Letters, and the Norwegian Ministry of Education and Research; the first prizes were awarded in 2008. Among the three winners of this year’s neuroscience award was the pioneering neuropsychologist Brenda Milner, whose work with Henry Molaison, or Patient H.M., led to […]

Read the full post

May 27, 2014

Scientist Goes 12 Years Without A Shower

Yep, twelve years without taking a single shower.  Incredible.  All in the name of science, of course.  And the amazing thing is that evidently you’ll never know it if you meet him. The scientist in question is David Whitlock (pictured at left), an MIT-trained chemical engineer and the inventor of AO+ Refreshing Cosmetic Mist.  AO+ is a “living bacterial skin tonic” that contains billions of Nitrosomonas Eutropha bacteria—a bacteria we normally wash away with soap and shampoo. I recently came across an article in the New York Times by the writer Julia Scott.  In this entertaining piece Scott describes her […]

Read the full post

May 23, 2014

Nurix Receives $21.5 M Series B Financing

Boston, MA-based Third Rock Ventures and San Francisco, CA-based The Column Group announced yesterday a $21.5M Series B investment round in drug discovery startup Nurix.  The larger investment comes after a 2012 seed round of $6.2M by the same investors. Nurix is working on novel therapies that target the ubiquitin proteasome system, or UBS, a regulatory pathway that breaks down unwanted proteins in cells.  According to an article in Xconomy yesterday, ubiquitins are like flags that attach themselves to proteins, “marking them for destruction within the proteasome, which are cylindrical chambers that function as disposal and recycling units within the […]

Read the full post

May 15, 2014

Nature Genomic Technologies & Biomaterials Conference At BIO 2014

Along with keynote speakers, partnering and networking opportunities, exhibitors, and panel discussions, this year’s BIO International Convention will also play host to a co-located conference on genomic technologies and biomaterials presented by Nature, Nature Biotechnology, and the Guangzhou Institutes of Biomedicine and Health. The conference, Genomic Technologies and Biomaterials for Understanding Disease, takes place on June 23 and 24, with sessions to be held on-location at the San Diego Convention Center. It is one of two co-located events at BIO this year.  The other is the International BioGENEius Challenge, a research contest for high school science students organized by the […]

Read the full post